Status:
COMPLETED
A Study of RO5093151 and RO5027838 in Patients With Type 2 Diabetes Mellitus on a Stable Dose of Metformin
Lead Sponsor:
Hoffmann-La Roche
Conditions:
Diabetes Mellitus Type 2
Eligibility:
All Genders
35-65 years
Phase:
PHASE2
Brief Summary
This 5 arm study will evaluate the efficacy and safety of RO5093151 and RO5027838 in patients with type 2 diabetes mellitus on a stable dose of metformin. After a 4 week pre-randomization period for g...
Eligibility Criteria
Inclusion
- adult patients, 35-65 years of age;
- type 2 diabetes for \>=3 months;
- treated for \>=3 months with stable dose of metformin \>=1.5g/day or maximum tolerated dose.
Exclusion
- history of diabetic ketoacidosis;
- currently or previously treated with insulin;
- currently or within previous 6 months treated with a thiazolidinedione or dual peroxisome proliferator activated receptor (PPAR) agonist;
- treated with lipoprotein-modifying therapy within a month before screening.
Key Trial Info
Start Date :
April 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2009
Estimated Enrollment :
110 Patients enrolled
Trial Details
Trial ID
NCT00823680
Start Date
April 1 2009
End Date
August 1 2009
Last Update
July 28 2016
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
Chula Vista, California, United States, 91911
2
Miami, Florida, United States, 330014
3
Graz, Austria, 8036
4
München, Germany, 80636